Treatment of neuronal ceroid lipofuscinosis

A method of therapeutic and/or prophylactic treatment of a human being for a Neuronal Ceroid Lipofuscinosis (NCL) or synucleinopathy or disease characterized by block of autophagic flow comprising administration to the human being a pharmaceutically effective and acceptable amount of a pro-cathepsin selected from the group consisting of pro-cathepsin D (proCTSD), pro-cathepsin B (proCTSB), and pro-cathepsin L (proCTSL), or any combination thereof,

• wherein said proCTSD comprises an amino acid sequence comprising a total of at most 20 amino acid substitutions and amino acid deletions compared SEQ ID NO:
• 3, and
• wherein said proCTSB comprises an amino acid sequence comprising a total of at most 20 amino acid substitutions and amino acid deletions compared to SEQ ID NO:
• 9, and
• wherein said proCTSL comprises an amino acid sequence comprising a total of at most 20 amino acid substitutions and amino acid deletions compared to SEQ ID NO:
• 14, and
• wherein said proCTSD or proCTSB or proCTSL is co-administered or formulated with an agent that facilitates passage of the proCTSD/proCTSB/proCTSL across the blood-brain barrier, or
• wherein the proCTSD/proCTSB/proCTSL is coupled to a moiety, which facilitates passage of the proCTSD/proCTSB/proCTSL across the blood-brain barrier.